¼¼°èÀÇ Æó ½ºÅÙÆ® ½ÃÀå
Pulmonary Stents
»óǰÄÚµå : 1788305
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 170 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License)
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)


Çѱ۸ñÂ÷

¼¼°èÀÇ Æó ½ºÅÙÆ® ½ÃÀåÀº 2030³â±îÁö 3¾ï 3,110¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 2¾ï 4,880¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ Æó ½ºÅÙÆ® ½ÃÀåÀº 2024-2030³â¿¡ CAGR 4.9%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 3¾ï 3,110¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ÀÚ±â È®ÀåÇü ½ºÅÙÆ®´Â CAGR 5.8%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 2¾ï 2,150¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. dz¼± È®ÀåÇü ½ºÅÙÆ® ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 3.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 6,540¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 4.7%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Æó ½ºÅÙÆ® ½ÃÀåÀº 2024³â¿¡ 6,540¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 5,320¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 4.7%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 4.6%¿Í 4.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è Æó ½ºÅÙÆ® ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

Æó ½ºÅÙÆ®°¡ È£Èí±â ÀÇ·á¿¡ ÇʼöÀûÀÎ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

Æó ½ºÅÙÆ®´Â ±â°üÁö ÇùÂø, Æó¾Ï, ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD), ¼ö¼ú ÈÄ ÇÕº´Áõ µîÀÇ ÁúȯÀ¸·Î ÀÎÇÑ ±âµµÆó¼â °ü¸®¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ ½ºÅÙÆ®´Â ±âµµÀÇ °³¹æ¼ºÀ» À¯ÁöÇÏ¿© ȯÀÚÀÇ È£ÈíÀ» µ½°í Àü¹ÝÀûÀÎ »îÀÇ ÁúÀ» Çâ»ó½ÃŰ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ȯ°æ¿À¿°, Èí¿¬, °í·ÉÈ­·Î ÀÎÇØ È£Èí±â ÁúȯÀÇ À¯º´·üÀÌ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó Æó ½ºÅÙÆ® ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ħ½ÀÀû ¼ö¼ú°ú ´Þ¸® ±â°üÁö°æ ½ºÅÙÆ® »ðÀÔ¼úÀº ÃÖ¼Ò Ä§½ÀÀû ¼Ö·ç¼ÇÀ» Á¦°øÇÏ¿© ȯÀÚÀÇ È¸º¹ ½Ã°£°ú ÀÔ¿ø ±â°£À» ´ÜÃà½Ãŵ´Ï´Ù. È£Èí±â Ä¡·á¿¡¼­ ¼ö¼úÀÌ ÇÊ¿ä ¾ø´Â Ä¡·á¹ýÀÌ ¼±È£µÇ¸é¼­ Æó ½ºÅÙÆ® ±â¼úÀÇ ¹ßÀüÀÌ ÃËÁøµÇ¾î º¸´Ù È¿°úÀûÀÌ°í ³»±¸¼ºÀÌ ¶Ù¾î³­ »ýüÀûÇÕ¼º ½ºÅÙÆ®°¡ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ÀÇ·áÁøÀº º¹ÀâÇÑ È£Èí±â ÁúȯÀ» °ü¸®Çϱâ À§ÇÑ Ä¡·á ÇÁ·ÎÅäÄÝ¿¡ Æó ½ºÅÙÆ®¸¦ Á¡Á¡ ´õ ¸¹ÀÌ µµÀÔÇϰí ÀÖÀ¸¸ç, Àü ¼¼°è º´¿ø°ú Àü¹® Ŭ¸®´Ð¿¡¼­ Æó ½ºÅÙÆ® »ç¿ëÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀ¸·Î Æó ½ºÅÙÆ®ÀÇ ¼º´ÉÀº ¾î¶»°Ô Çâ»óµÇ°í Àִ°¡?

ÃÖ±Ù Æó ½ºÅÙÆ® ¼³°è ¹× Àç·áÀÇ ±â¼ú Çõ½ÅÀ¸·Î ÀÓ»ó È¿°ú¿Í ȯÀÚ ¿¹Èİ¡ Å©°Ô Çâ»óµÇ¾ú½À´Ï´Ù. ±âÁ¸ÀÇ ±Ý¼Ó ½ºÅÙÆ®³ª ½Ç¸®ÄÜ ½ºÅÙÆ®´Â ÀüÀÌ À§ÇèÀ» ÃÖ¼ÒÈ­ÇÏ°í ±âµµ³» Àå±âÀûÀÎ ¾ÈÁ¤¼ºÀ» Çâ»ó½Ã۱â À§ÇØ °³¼±µÇ¾î ¿Ô½À´Ï´Ù. ±âµµÀÇ À±°û¿¡ ÀûÀÀÇϰí ÀæÀº À§Ä¡ º¯°æÀÇ Çʿ伺À» ÁÙ¿©ÁÖ´Â ÀÚ°¡ È®ÀåÇü ½ºÅÙÆ®ÀÇ µµÀÔÀ¸·Î ½Ã¼úÀÇ ¼º°ø·üÀ» Çâ»ó½ÃÄ×½À´Ï´Ù. ¶ÇÇÑ Ç׿°Áõ¾à³ª Ç×Áõ½ÄÁ¦·Î ÄÚÆÃµÈ ¾àÁ¦¿ëÃ⼺ ½ºÅÙÆ®´Â ÀçÇùÂøÀ» ¿¹¹æÇÏ°í ¹Ýº¹ÀûÀÎ ÁßÀç½Ã¼úÀÇ °¡´É¼ºÀ» ÁÙÀ̱â À§ÇØ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ½Ã°£ÀÌ Áö³²¿¡ µû¶ó ¼­¼­È÷ ¿ëÇØµÇ´Â »ýüÈí¼ö¼º ½ºÅÙÆ®´Â ÀϽÃÀûÀÎ ±âµµ Áö¿øÀ» À§ÇÑ À¯¸Á ´ë¾ÈÀ¸·Î ºÎ»óÇϰí ÀÖÀ¸¸ç, ½ºÅÙÆ® Á¦°Å ½Ã¼úÀÇ Çʿ伺À» ¾ø¾Ö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ °íÇØ»óµµ CT ½ºÄµ, À¯µµÇÏ ±â°üÁö°æ µî ¿µ»ó±â¼úÀÇ Çâ»óÀ¸·Î ½ºÅÙÆ® »ðÀÔÀÇ Á¤È®µµ°¡ Çâ»óµÇ°í ÇÕº´ÁõÀÌ °¨¼ÒÇÏ¿© Ä¡·á°á°ú°¡ ÃÖÀûÈ­µÇ°í ÀÖ½À´Ï´Ù. ½ºÅÙÆ®ÀÇ À¯¿¬¼º, »ýüÀûÇÕ¼º ¹× Àå±âÀû À¯È¿¼º Çâ»ó¿¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸°¡ °è¼ÓµÇ°í ÀÖÀ¸¸ç, Â÷¼¼´ë Æó ½ºÅÙÆ®´Â È£Èí±â ÀÇÇÐÀÇ »õ·Î¿î Ç¥ÁØÀ» Á¦½ÃÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

Æó ½ºÅÙÆ® äÅÃÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

Æó ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í Àúħ½ÀÀû Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Æó ½ºÅÙÆ®¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ȯÀÚ¿Í ÀÇ·áÁøµéÀº ±â°üÁö°æÇÏ ½ºÅÙÆ® »ðÀÔ¼úÀÌ ±âÁ¸ÀÇ °³º¹ ¼ö¼úº¸´Ù À§Ç輺ÀÌ ³·°í ȸº¹ÀÌ ºü¸£¸ç ȯÀÚÀÇ ÆíÀǼºÀÌ Çâ»óµÇ¾î ±âÁ¸ °³º¹ ¼ö¼úº¸´Ù ±â°üÁö°æÇÏ ½ºÅÙÆ® »ðÀÔ¼úÀ» ¼±È£Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ °í·ÉÈ­ »çȸ¿¡¼­ Æó¾Ï ¹ßº´·ü Áõ°¡´Â ±âµµ °ü¸® ¼Ö·ç¼ÇÀÇ Çʿ伺À» ´õ¿í °¡¼ÓÈ­½Ã۰í ÀÖÀ¸¸ç, Æó ½ºÅÙÆ®´Â ÁøÇ༺ ¾Ï ȯÀÚÀÇ ¿ÏÈ­Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ´ë±â¿À¿°°ú Èí¿¬ ½À°üÀ¸·Î ÀÎÇÑ COPD ȯÀÚ°¡ Àü ¼¼°è¿¡¼­ Áõ°¡ÇÔ¿¡ µû¶ó ±âµµ Æó¼â¸¦ È¿°úÀûÀ¸·Î °ü¸®Çϱâ À§ÇÑ ½ºÅÙÆ® »ðÀÔÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±Ý¼Ó°ú ½Ç¸®ÄÜÀÇ ÀåÁ¡À» °áÇÕÇÑ ÇÏÀ̺긮µå µðÀÚÀÎ µî ½ºÅÙÆ® Á¦Á¶ÀÇ ±â¼úÀû Áøº¸µµ ³»±¸¼º°ú ±â´É¼ºÀ» Çâ»ó½ÃÄÑ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¸¹Àº ¼±Áø±¹¿¡¼­ ÆóÁßÀç¿¡ ´ëÇÑ »óȯ Á¤Ã¥À» ÀÌ¿ëÇÒ ¼ö ÀÖ´Â °ÍÀº º´¿ø°ú Àü¹® Ŭ¸®´ÐÀÌ ±âµµ °ü¸®¸¦ À§ÇØ ÀÌ·¯ÇÑ ÀåÄ¡¸¦ äÅÃÇÏ´Â °ÍÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

Æó ½ºÅÙÆ® ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?

¼¼°è Æó ½ºÅÙÆ® ½ÃÀåÀÇ ¼ºÀåÀº ¸¸¼º È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡, ½ºÅÙÆ® ¼³°è ¹× Àç·áÀÇ ¹ßÀü, Àúħ½ÀÀû ±âµµ °ü¸® ±â¼úÀÇ Ã¤Åà Áõ°¡ µî ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ½ÅÈï ½ÃÀåÀÇ ÀÇ·á ÀÎÇÁ¶ó È®´ë´Â °í±Þ È£Èí±â Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» Çâ»ó½ÃÄÑ Æó ½ºÅÙÆ®¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ AI¸¦ Ȱ¿ëÇÑ ¿µ»óó¸®¿Í ·Îº¿ º¸Á¶ ±â°üÁö°æÀÇ ÅëÇÕÀ¸·Î ½Ã¼úÀÇ Á¤È®µµ°¡ Çâ»óµÇ°í, ½ºÅÙÆ® »ðÀÔÀÌ º¸´Ù È¿°úÀûÀ¸·Î ÀÌ·ç¾îÁö¸ç, ÇÕº´Áõ ¹ß»ý·üÀÌ °¨¼ÒÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ, ¿¬±¸ ±â°ü ¹× ÀÇ·á±â±â Á¦Á¶¾÷üÀÇ È£Èí±â Ä¡·á¿¡ ´ëÇÑ ÅõÀÚ È®´ë´Â Æó ½ºÅÙÆ® ±â¼úÀÇ Çõ½ÅÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. Â÷¼¼´ë ½ºÅÙÆ®¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀº ÀÇ·á±â±â Á¦Á¶¾÷ü¿Í ÀÇ·á ±â°ü°úÀÇ Çù·Â °ü°è Áõ°¡¿Í ÇÔ²² ½ÃÀå È®´ë¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. È¿°úÀûÀÎ ±âµµ °ü¸® ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó Æó ½ºÅÙÆ® ½ÃÀåÀº È£Èí±â Ä¡·áÀÇ ¹Ì·¡¸¦ Çü¼ºÇÏ´Â Áö¼ÓÀûÀÎ ¹ßÀü°ú ÇÔ²² Áö¼ÓÀûÀ¸·Î ¹ßÀüÇÒ Å¼¼¸¦ °®Ãß°í ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç°(ÀÚ±â È®ÀåÇü ½ºÅÙÆ®, dz¼± È®ÀåÇü ½ºÅÙÆ®), Àç·á(±Ý¼Ó, ½Ç¸®ÄÜ, ÇÏÀ̺긮µå), À¯Çü(±â°ü ±â°üÁö ½ºÅÙÆ®, ÈĵΠ½ºÅÙÆ®)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Pulmonary Stents Market to Reach US$331.1 Million by 2030

The global market for Pulmonary Stents estimated at US$248.8 Million in the year 2024, is expected to reach US$331.1 Million by 2030, growing at a CAGR of 4.9% over the analysis period 2024-2030. Self-expandable Stents, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$221.5 Million by the end of the analysis period. Growth in the Balloon-expandable Stents segment is estimated at 3.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$65.4 Million While China is Forecast to Grow at 4.7% CAGR

The Pulmonary Stents market in the U.S. is estimated at US$65.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$53.2 Million by the year 2030 trailing a CAGR of 4.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.6% and 4.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global Pulmonary Stents Market - Key Trends & Drivers Summarized

Why Are Pulmonary Stents Becoming Essential in Respiratory Medicine?

Pulmonary stents play a crucial role in managing airway obstruction caused by conditions such as tracheobronchial stenosis, lung cancer, chronic obstructive pulmonary disease (COPD), and post-surgical complications. These stents help maintain airway patency, allowing patients to breathe more easily and improving overall quality of life. As the prevalence of respiratory disorders continues to rise due to environmental pollution, smoking, and aging populations, the demand for pulmonary stents has grown significantly. Unlike invasive surgical procedures, stent placement via bronchoscopy offers a minimally invasive solution, reducing patient recovery time and hospital stays. The increasing preference for non-surgical interventions in respiratory care has driven advancements in pulmonary stent technology, making them more effective, durable, and biocompatible. Healthcare providers are increasingly incorporating pulmonary stents into treatment protocols to manage complex airway diseases, leading to expanded adoption across hospitals and specialty clinics worldwide.

How Are Technological Advancements Improving Pulmonary Stent Performance?

Recent innovations in pulmonary stent design and materials have significantly enhanced their clinical efficacy and patient outcomes. Traditional metal and silicone stents have been refined to minimize migration risks and improve long-term stability within the airways. The introduction of self-expanding stents, which adapt to airway contours and reduce the need for frequent repositioning, has improved procedural success rates. Furthermore, drug-eluting pulmonary stents, coated with anti-inflammatory or anti-proliferative agents, are being developed to prevent restenosis and reduce the likelihood of repeat interventions. Bioresorbable stents, which gradually dissolve over time, are emerging as a promising alternative for temporary airway support, eliminating the need for stent removal procedures. Enhanced imaging technologies such as high-resolution CT scans and guided bronchoscopy have also improved the precision of stent placement, reducing complications and optimizing treatment outcomes. As research continues to focus on improving stent flexibility, biocompatibility, and long-term efficacy, the next generation of pulmonary stents is expected to set new standards in respiratory medicine.

What Factors Are Driving the Adoption of Pulmonary Stents?

The increasing prevalence of lung diseases, coupled with rising awareness about minimally invasive treatment options, has fueled the demand for pulmonary stents. Patients and healthcare providers are favoring bronchoscopic stenting over traditional open surgeries due to lower risks, faster recovery times, and improved patient comfort. The rising incidence of lung cancer, particularly in aging populations, has further accelerated the need for airway management solutions, with pulmonary stents being widely used for palliative care in advanced-stage cancer patients. Additionally, the growing number of COPD cases worldwide, driven by air pollution and smoking habits, has led to increased stent placements to manage airway obstruction effectively. Technological advancements in stent manufacturing, such as hybrid designs that combine the benefits of metal and silicone, are also contributing to market growth by offering enhanced durability and functionality. The availability of reimbursement policies for pulmonary interventions in many developed countries is further encouraging hospitals and specialty clinics to adopt these devices for airway management.

What Are the Key Drivers Fueling Growth in the Pulmonary Stents Market?

The growth in the global pulmonary stents market is driven by several key factors, including the rising incidence of chronic respiratory diseases, advancements in stent design and materials, and the increasing adoption of minimally invasive airway management techniques. The expansion of healthcare infrastructure, particularly in emerging markets, is improving access to advanced respiratory treatments, boosting demand for pulmonary stents. The integration of AI-powered imaging and robotic-assisted bronchoscopy is also enhancing procedural accuracy, making stent placement more effective and reducing complication rates. Furthermore, the growing investment in respiratory care by healthcare providers, research institutions, and medical device manufacturers is accelerating innovation in pulmonary stent technology. Regulatory approvals for next-generation stents, along with increasing collaborations between medical device companies and healthcare organizations, are further driving market expansion. As the demand for effective airway management solutions continues to grow, the pulmonary stents market is poised for sustained development, with ongoing advancements shaping the future of respiratory care.

SCOPE OF STUDY:

The report analyzes the Pulmonary Stents market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Self-expandable Stents, Balloon-expandable Stents); Material (Metal, Silicon, Hybrid); Type (Tracheobronchial Stents, Laryngeal Stents)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â